At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 66 target
Drug / intervention
BL-B01D1 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT06437509Phase 2RecruitingMonitorUpdated 13mo ago · Completion was 1mo agoSlow Enrollment
Monitor
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Extensive-stage Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating BL-B01D1 and PD-1 monoclonal antibody for Extensive-stage Small-cell Lung Cancer. Currently recruiting, targeting 66 participants across 1 site.
Signals
Enrolling slower than its timeline implies
Detailed Summary
This study is a phase II clinical study to explore the efficacy and safety of BL-B01D1 + PD-1 monoclonal antibody combination therapy in patients with extensive-stage small cell lung cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsExtensive-stage Small-cell Lung Cancer
CountriesChina
CollaboratorsBaili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Timeline
Phase 2RecruitingOverdue
20252026
First PostedMay 2024
Enrollment StartJun 2024
Primary CompletionJun 2026
TodayJul 2026
First PostedMay 31, 2024
Enrollment StartJun 13, 2024
Primary CompletionJun 1, 2026
TodayJul 1, 2026
Enrollment to primary: 2.0 yearsPosted 2.1 years ago
Interventions
BL-B01D1drug
Administration by intravenous infusion for a cycle of 3 weeks.
PD-1 monoclonal antibodydrug
Administration by intravenous infusion for a cycle of 3 weeks.